Actively Recruiting
AI-Based Mobile Intervention on Medication Non-Adherence and Transition in Adolescents and Young Adults with Epilepsy
Led by University of Central Florida · Updated on 2026-05-29
200
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Central Florida
Lead Sponsor
A
American Epilepsy Society
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of an AI-personalized mobile app called Medilepsy in improving medication adherence and transition readiness among underserved adolescents and young adults with epilepsy, ages 14 to 24, in Florida. This study compares the AI-enhanced version of the app with a standard version that does not include AI personalization. The research focuses on key outcomes including medical adherence, usability, and language experience. Participants are randomly assigned to one of two groups: the intervention group uses the AI-personalized Medilepsy app with an interactive Smart Chatbot that provides tailored prompts, adaptive education, and personalized support for epilepsy self-management. The comparison group receives a standard version of the Medilepsy app, which offers static prompts and general educational content without personalized feedback. The study lasts 3 to 6 months, during which participants use their assigned app version. During the study, participants will be monitored for medication adherence and transition readiness skills through app usage and assessments. Researchers will evaluate the usability of the app at the end of the 3 to 6 month period. The study collects data on how well the AI features support epilepsy management compared to the standard app version. Safety and participant engagement are also observed throughout the trial duration.
CONDITIONS
Brief Title
AI-Based Mobile Intervention on Medication Non-Adherence and Transition
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with epilepsy
- Currently prescribed anti-seizure medicine (ASMs)
- Identified as part of an underserved population, such as being from a racial or ethnic group underrepresented in healthcare or having low income
- Aged 14-17 years and able to provide assent, with a parent or legal guardian present to receive app notifications
- Aged 18-24 years and able to provide informed consent
- Able to read, speak, and write in English
- Resides in Florida
- Receives outpatient medical services
You will not qualify if you...
- Does not own a mobile device with internet access
- Has a history of severe intellectual disability
- Unable to operate a mobile device using keyboard or touchscreen
- Resides in an in-patient setting
- Adults unable to provide consent
- Pregnant women
- Prisoners
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 to 6 months
Participants use either the AI-personalized Medilepsy® app or the standard version to support epilepsy self-management.
Participants use the app throughout the treatment period with regular interaction but no scheduled visits
Trial Site Locations
Total: 2 locations
1
Orlando Health Arnold Palmer Hospital
Orlando, Florida, United States, 32806
Actively Recruiting
2
Orlando Health Orlando Regional Medical Center
Orlando, Florida, United States, 32806
Actively Recruiting
Research Team
M
Michelle Tall, PhD, RN, FAES
A
Amoy Fraser, PhD, CCRP, PMP
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here